Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper

Most anticancer molecules are administered in body-size-based dosing schedules, bringing up unsolved issues regarding pharmacokinetic data in heavy patients. The worldwide spread of obesity has not been matched by improved methods and strategies for tailored drug dosage in this population. The weigh...

Descripción completa

Detalles Bibliográficos
Autores principales: Silvestris, N., Argentiero, A., Natalicchio, A., D'Oronzo, S., Beretta, G.D., Acquati, S., Adinolfi, V., Di Bartolo, P., Danesi, R., Faggiano, A., Ferrari, P., Gallo, M., Gori, S., Morviducci, L., Russo, A., Tuveri, E., Zatelli, M.C., Montagnani, M., Giorgino, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134762/
https://www.ncbi.nlm.nih.gov/pubmed/33984679
http://dx.doi.org/10.1016/j.esmoop.2021.100153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134762/
https://www.ncbi.nlm.nih.gov/pubmed/33984679
http://dx.doi.org/10.1016/j.esmoop.2021.100153

Ejemplares similares